Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

This is a single-arm, exploratory study. People with recurrent platinum-resistant ovarian cancer who have not received any previous systemic antitumor therapy for ovarian cancer were selected to evaluate the efficacy and safety of adebrelimab combined with fuzuloparib.

Trial Details

NCT ID
NCT05753826
Phase
PHASE2
Sponsor
Fujian Cancer Hospital
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Adebrelimab
  • Fuzuloparib
Locations (sample)
  • Fujian, China|28.92651,106.12972

Key Eligibility Criteria

  • Age 18-70;Female;
  • Pathologically (including histologically) confirmed epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (hereinafter refe…
  • Patients have at least one target lesion with measurable dimensions according to RECIST1.1 criteria;
  • HRR gene mutation confirmed by testing tissue or blood samples;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →